CNB-001, a synthesized derivative of curcumin, activates CaMKII and enhances memory

Research Project

Project/Area Number	24790540
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Applied pharmacology
Research Institution	Musashino University
Principal Investigator	AKAISHI TATSUHIRO 武蔵野大学, 薬学研究所, 講師 (90386384)
Project Period (FY)	2012-04-01 – 2015-03-31
Project Status	Completed (Fiscal Year 2014)
Budget Amount *help	¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000) Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Keywords	クルクミン / 海馬 / 長期増強 / 記憶 / CaMKⅡ / CaMKII / アルツハイマー病 / 認知症
Outline of Final Research Achievements	We have recently demonstrated that oral administration of CNB-001, a synthesized pyrazole derivative of curcumin, enhances memory in a rat object recognition test. CNB-001 could be useful in the development of therapeutic drugs for senile dementia. This study investigated mechanisms underlying the memory-enhancing effect of CNB-001, and found that CNB-001 promoted NMDA receptor- and CaMKII-dependent long-term potentiation (LTP) of rat hippocampal slices, not via the MAP kinase or PKC cascade.

Report

(4 results)